The GA in HSI Study

Annotation of Geographic Atrophy in Hyperspectral Images Captured With the Optina-4C™

This study used a retrospective dataset collected by Optina under different study protocols. The target study population will include adults over the age of 50 years, with and without the presence of AMD.

Study Overview

• Status: Completed
• Conditions: Healthy; Geographic Atrophy
• Intervention / Treatment: Other: Retrospective Study

Detailed Description

This retrospective, case-control study used the clinical data previously collected by Optina (CIP 22-003 AND Study, CIP 22-004 CAS Training Study and RWD 24-011 RWD Study). As such, no new participants were enrolled for this study. The review and annotation of the MHRC H5 Images for GA are within the scope of each of these studies and the study participants have provided their Informed Consent for use of their retinal scans to assess clinical diagnostic applications. Images from the above-mentioned studies that met the inclusion criteria (there were no exclusion criteria) were classified into 3 different cohorts per the selection process described in the Study Protocol. Each cohort required a minimum of 10 MHRC Images from unique eyes with matched OCT scans.

• Cohort A: Eyes of patients with a diagnosis of dry AMD with GA lesions:

  o This cohort included patients with intermediate-or late-stage dry AMD where GA lesions are present, based on either the diagnostic information provided by the clinic, or by visible assessment of either the HSI or OCT images performed by the Optina Analyst.

• Cohort B: Eyes of patients with diagnosis of dry AMD without the presence of GA lesions

  o This cohort included patients with early or intermediate dry AMD where GA lesions are not present, based on either the diagnostic information provided by the clinic, or by visible assessment of either the HSI or OCT images performed by the Optina Analyst.

• Cohort C: Eyes of age-matched healthy patients (no AMD or GA lesions)

  • This cohort included patients with healthy retinas, based on either the diagnostic information provided by the clinic, or by visible assessment of either the HSI or OCT images performed by the Optina Analyst. Knowledge Transfer and Training Optina facilitated a Knowledge Transfer and Training session by the IOI for CapeStart Study Personnel.

CapeStart Study Personnel were trained in using Optivizon Viewing Software, the viewing software included in the marketed version of Optina-4C (MHRC device), and the Optina Segmentation tool.

Additionally, they were trained in the presentation of GA in HSI Images. Evaluation Phase CapeStart were provided with the Test Dataset of eye scans (n=40 eyes). CapeStart Optometristsreviewed all the HSI Images from the Optina-4C in Optivizon, annotated any GA lesions (if present) in the RelSpec@560 image using the Optina Segmentation tool, and completed the HSI Questionnaire for the MHRC H5 Images. Annotation Process The HSI RelSpec@560 Images were annotated by the CapeStart Optometrists for the Evaluation Phase.

The annotations were completed using the validated Optina Segmentation Tool per the User Manual, and all image annotations were performed on the Virtual Machine established and validated by Optina for this study.

If the eye was considered to have at least one GA lesion after viewing the MHRC H5 Images in Optivizon, the RelSpec@560 Image was annotated using the Optina Segmentation Tool. The annotator used the yellow label for high confidence level for GA visualization and Blue label for low confidence level.

Reference Data The IOI was responsible for generating the reference data. The IOI reviewed all OCT images as well as the MHRC H5 Images, then annotated the RelSpec@560 images. The IOI visual assessment made note of all cRORA (GA lesions) and iRORA (nascent GA lesion) in the OCT and aligned where possible with corresponding lesions in the HSI images. Lastly, the IOI completed the HSI Questionnaire for all annotated Relspec images.

• Study Type: Observational
• Enrollment (Actual): 42

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montréal, Quebec, Canada, H4P 2P5
      • Optina Diagnostics Inc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

This study will use a retrospective dataset collected by Optina under different study protocols. The target study population will include adults over the age of 50 years, with and without the presence of AMD.

Description

Inclusion Criteria:

Participants may enter the study only if ALL the following inclusion criteria are present:

• Study participants over the age of 50 years who consented to participate in Optina studies CIP-22-003, CIP-22-004, DOC100463, or RWD-24-011.
• MHRC H5 Image Cube has been reviewed by an Optina Analyst and identified as aligned with the Target Population (see Section 5.2).
• MHRC H5 Image Cube has a corresponding OCT image.

Exclusion Criteria:

• No exclusion criteria.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cohort A; Eyes of patients with a diagnosis of dry AMD with GA lesions	Other: Retrospective Study; Retrospective Study This study will use a retrospective Test Dataset of eye scans collected by Optina under different study protocols. MHRC H5 Images collected as part of Optina studies CIP-22-003, CIP-22-004, DOC100463 or RWD-24-011 will be reviewed by an Optina Data Analyst and flagged for potential match to the Target Population. Of the flagged images, 40 will be selected and allocated to the Test Dataset. All selected images must have a matching OCT image for review as part of the Reference Data. The Test Dataset will be documented in the CIP-24-015 data spreadsheet and archived in the CIP-24-015 central files.
Cohort B; Eyes of patients with a diagnosis of AMD without the presence of RPE disruptions	Other: Retrospective Study; Retrospective Study This study will use a retrospective Test Dataset of eye scans collected by Optina under different study protocols. MHRC H5 Images collected as part of Optina studies CIP-22-003, CIP-22-004, DOC100463 or RWD-24-011 will be reviewed by an Optina Data Analyst and flagged for potential match to the Target Population. Of the flagged images, 40 will be selected and allocated to the Test Dataset. All selected images must have a matching OCT image for review as part of the Reference Data. The Test Dataset will be documented in the CIP-24-015 data spreadsheet and archived in the CIP-24-015 central files.
Cohort C; Eyes of age-matched healthy patients (no AMD or GA lesions)	Other: Retrospective Study; Retrospective Study This study will use a retrospective Test Dataset of eye scans collected by Optina under different study protocols. MHRC H5 Images collected as part of Optina studies CIP-22-003, CIP-22-004, DOC100463 or RWD-24-011 will be reviewed by an Optina Data Analyst and flagged for potential match to the Target Population. Of the flagged images, 40 will be selected and allocated to the Test Dataset. All selected images must have a matching OCT image for review as part of the Reference Data. The Test Dataset will be documented in the CIP-24-015 data spreadsheet and archived in the CIP-24-015 central files.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the total number of Relspec images annotated for GA lesions	Comparison of the total number of Relspec images annotated for GA lesions of at least 29 pixels or larger with the total number of OCT images with identified GA lesions (cRORA) in the Test Dataset.	45 days
Comparison of the total number of 'high certainty' GA lesions	Comparison of the total number of 'high certainty' GA lesions (Yellow label) of at least 29 pixels annotated in all Relspec images with the total number of (cRORA) identified in the OCT images in the Test Dataset.	45 days
Comparison of the total number of GA lesions	Comparison of the total number of GA lesions (Yellow label and Dark Blue label) of at least 29 pixels or larger annotated in all Relspec images with the total number of identified GA lesions (cRORA) in the OCT images in the Test Dataset.	45 days
Evaluation of the Global DICE Score	Evaluation of the Global DICE Score for annotations of 29 pixels or larger performed by CapeStart compared with the Reference Data.	45 days

Collaborators and Investigators

• Sponsor: Optina Diagnostics Inc.
• Investigators: Principal Investigator: Ramina Nissan, OD, The Glen Site, McGill University Health Centre

Study record dates

Study Major Dates

• Study Start (Actual): December 24, 2024
• Primary Completion (Actual): February 18, 2025
• Study Completion (Actual): February 18, 2025

Study Registration Dates

• First Submitted: February 28, 2025
• First Submitted That Met QC Criteria: February 28, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 28, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Eye Diseases; Retinal Diseases; Retinal Degeneration; Macular Degeneration; Atrophy; Geographic Atrophy
• Other Study ID Numbers: CIP-24-015

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No